Loading clinical trials...
Loading clinical trials...
A Phase 0/Ia Study of BI 907828 (Brigimadlin) Concentrations in Brain Tissue and a Non-randomized Open-label, Dose Escalation Study of BI 907828 (Brigimadlin) in Combination With Radiotherapy in Patients With Newly Diagnosed Glioblastoma
Conditions
Interventions
BI 907828 (Brigimadlin)
Locations
7
United States
Mayo Clinic-Arizona
Phoenix, Arizona, United States
Yale New Haven Hospital
New Haven, Connecticut, United States
Mayo Clinic Cancer Center
Jacksonville, Florida, United States
Mayo Clinic, Rochester
Rochester, Minnesota, United States
UZ Leuven
Leuven, Belgium
Hospital del Mar
Barcelona, Spain
Start Date
November 30, 2022
Primary Completion Date
July 31, 2025
Completion Date
July 31, 2025
Last Updated
August 24, 2025
NCT05969860
NCT02800486
NCT05789394
NCT06934889
NCT05283330
NCT00083512
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions